1. International Diabetes Federation. IDF diabetes atlas. 9th ed. Brussels: IDF; 2019 [cited 2021 Sep 25]. Available from:
www.diabetesatlas.org/en.
2. Cook CB, Kongable GL, Potter DJ, Abad VJ, Leija DE, Anderson M. Inpatient glucose control: a glycemic survey of 126 U.S. hospitals. J Hosp Med 2009;4:E7-14.
Article
3. Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 2003;78:1471-8.
Article PubMed
4. Holman N, Knighton P, Kar P, O’Keefe J, Curley M, Weaver A, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol 2020;8:823-33.
Article PubMed PMC
5. van den Boom W, Schroeder RA, Manning MW, Setji TL, Fiestan GO, Dunson DB. Effect of A1C and glucose on postoperative mortality in noncardiac and cardiac surgeries. Diabetes Care 2018;41:782-8.
Article PubMed
6. Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 2011;34:256-61.
Article PubMed PMC
7. Bagshaw SM, Egi M, George C, Bellomo R; Australia New Zealand Intensive Care Society Database Management Committee. Early blood glucose control and mortality in critically ill patients in Australia. Crit Care Med 2009;37:463-70.
Article PubMed
8. Kosiborod M, Rathore SS, Inzucchi SE, Masoudi FA, Wang Y, Havranek EP, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation 2005;111:3078-86.
Article PubMed
9. Kosiborod M, Inzucchi SE, Krumholz HM, Xiao L, Jones PG, Fiske S, et al. Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation 2008;117:1018-27.
Article PubMed
10. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-97.
Article PubMed
11. Queale WS, Seidler AJ, Brancati FL. Glycemic control and sliding scale insulin use in medical inpatients with diabetes mellitus. Arch Intern Med 1997;157:545-52.
Article PubMed
12. Browning LA, Dumo P. Sliding-scale insulin: an antiquated approach to glycemic control in hospitalized patients. Am J Health Syst Pharm 2004;61:1611-4.
Article PubMed
13. Hirsch IB. Sliding scale insulin: time to stop sliding. JAMA 2009;301:213-4.
PubMed
14. Golightly LK, Jones MA, Hamamura DH, Stolpman NM, McDermott MT. Management of diabetes mellitus in hospitalized patients: efficiency and effectiveness of sliding-scale insulin therapy. Pharmacotherapy 2006;26:1421-32.
Article PubMed
15. Umpierrez GE, Palacio A, Smiley D. Sliding scale insulin use: myth or insanity? Am J Med 2007;120:563-7.
Article PubMed
16. Sheu WH, Ji L, Lee WJ, Jabbar A, Han JH, Lew T. Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: a systematic review. J Diabetes Investig 2017;8:518-34.
Article PubMed PMC
17. Ji LN, Lu JM, Guo XH, Yang WY, Weng JP, Jia WP, et al. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health 2013;13:602.
Article PubMed PMC
18. Freemantle N, Balkau B, Danchin N, Wang E, Marre M, Vespasiani G, et al. Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetes. Diabetes Obes Metab 2012;14:901-9.
Article PubMed PMC
19. Roberts GW, Aguilar-Loza N, Esterman A, Burt MG, Stranks SN. Basal-bolus insulin versus sliding-scale insulin for inpatient glycaemic control: a clinical practice comparison. Med J Aust 2012;196:266-9.
Article PubMed
20. Zaman Huri H, Permalu V, Vethakkan SR. Sliding-scale versus basal-bolus insulin in the management of severe or acute hyperglycemia in type 2 diabetes patients: a retrospective study. PLoS One 2014;9:e106505.
Article PubMed PMC
21. Cefalu WT, Dawes DE, Gavlak G, Goldman D, Herman WH, Van Nuys K, et al. Insulin Access and Affordability Working Group: conclusions and recommendations. Diabetes Care 2018;41:1299-311.
Article PubMed
22. Hirao K, Arai K, Yamauchi M, Takagi H, Kobayashi M; Japan Diabetes Clinical Data Management Study Group. Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11). Diabetes Res Clin Pract 2008;79:171-6.
Article PubMed
23. Jeong IK, Chung CH, Zhou Z, Han JH, Duan R, Edralin DM, et al. Comparison of insulin intensification strategies with insulin lispro low mixture twice daily versus basal insulin glargine and prandial insulin lispro once daily in East Asian and Caucasian patients with type 2 diabetes mellitus. J Diabetes 2017;9:396-404.
PubMed
24. Ji L, Min KW, Oliveira J, Lew T, Duan R. Comparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study. Diabetes Metab Syndr Obes 2016;9:243-9.
PubMed PMC
25. Masuda H, Sakamoto M, Irie J, Kitaoka A, Shiono K, Inoue G, et al. Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naïve type 2 diabetic patients. Diabetes Obes Metab 2008;10:1261-5.
Article PubMed
26. Jin SM, Kim JH, Min KW, Lee JH, Ahn KJ, Park JH, et al. Basalprandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: a 24-week randomized non-inferiority trial. J Diabetes 2016;8:405-13.
Article PubMed
27. Jia W, Xiao X, Ji Q, Ahn KJ, Chuang LM, Bao Y, et al. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial. Lancet Diabetes Endocrinol 2015;3:254-62.
Article PubMed
28. Anyanwagu U, Mamza J, Gordon J, Donnelly R, Idris I. Premixed vs basal-bolus insulin regimen in Type 2 diabetes: comparison of clinical outcomes from randomized controlled trials and real-world data. Diabet Med 2017;34:1728-36.
Article PubMed
29. Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007;30:2181-6.
Article PubMed
30. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011;10:150-61.
Article PubMed
31. American Diabetes Association. 15. Diabetes care in the hospital: standards of medical care in diabetes-2021. Diabetes Care 2021;44(Suppl 1):S211-20.
PubMed
32. Bellido V, Suarez L, Rodriguez MG, Sanchez C, Dieguez M, Riestra M, et al. Comparison of basal-bolus and premixed insulin regimens in hospitalized patients with type 2 diabetes. Diabetes Care 2015;38:2211-6.
Article PubMed PMC
33. Alvarenga MA, Komatsu WR, de Sa JR, Chacra AR, Dib SA. Clinical inertia on insulin treatment intensification in type 2 diabetes mellitus patients of a tertiary public diabetes center with limited pharmacologic armamentarium from an upper-middle income country. Diabetol Metab Syndr 2018;10:77.
Article PubMed PMC
34. Lovshin JA, Zinman B. Diabetes: clinical inertia: a barrier to effective management of T2DM. Nat Rev Endocrinol 2013;9:635-6.
Article PubMed
35. Blak BT, Smith HT, Hards M, Curtis BH, Ivanyi T. Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin. Diabet Med 2012;29:e13-20.
Article PubMed
36. Holt RI. Insulin initiation in type 2 diabetes: the implications of the 4-T study. Diabet Med 2010;27:1-3.
Article
37. Liebl A. Insulin intensification: the rationale and the target. Int J Clin Pract Suppl 2009;164:1-5.
38. Cho YM. To mix or to separate: that is the question. Lancet Diabetes Endocrinol 2015;3:229-31.
Article PubMed
39. Kalra S, Balhara YP, Sahay BK, Ganapathy B, Das AK. Why is premixed insulin the preferred insulin?: novel answers to a decade-old question. J Assoc Physicians India 2013;61(1 Suppl):9-11.
40. Wilson M, Weinreb J, Hoo GW. Intensive insulin therapy in critical care: a review of 12 protocols. Diabetes Care 2007;30:1005-11.
Article PubMed
41. Zhang X, Zhang T, Xiang G, Wang W, Li Y, Du T, et al. Comparison of weight-based insulin titration (WIT) and glucose-based insulin titration using basal-bolus algorithm in hospitalized patients with type 2 diabetes: a multicenter, randomized, clinical study. BMJ Open Diabetes Res Care 2020;8:e001261.
Article PubMed PMC
42. Wexler DJ, Shrader P, Burns SM, Cagliero E. Effectiveness of a computerized insulin order template in general medical inpatients with type 2 diabetes: a cluster randomized trial. Diabetes Care 2010;33:2181-3.
Article PubMed PMC
43. Aloi J, Bode BW, Ullal J, Chidester P, McFarland RS, Bedingfield AE, et al. Comparison of an electronic glycemic management system versus provider-managed subcutaneous basal bolus insulin therapy in the hospital setting. J Diabetes Sci Technol 2017;11:12-6.
Article PubMed
44. Li X, Du T, Li W, Zhang T, Liu H, Xiong Y. Efficacy and safety of weight-based insulin glargine dose titration regimen compared with glucose level- and current dose-based regimens in hospitalized patients with type 2 diabetes: a randomized, controlled study. Clin Ther 2014;36:1269-75.
Article PubMed
45. Davis S, Friece C, Roderman N, Newcomer D, Castaneda E. Comparison of insulin detemir and insulin glargine for hospitalized patients on a basal-bolus protocol. Pharmacy (Basel) 2017;5:22.
Article PMC
46. Lorenz E, Kopke S, Pfaff H, Blettner M. Cluster-randomized studies. Dtsch Arztebl Int 2018;115:163-8.
Article PubMed PMC
47. Campbell MK, Mollison J, Steen N, Grimshaw JM, Eccles M. Analysis of cluster randomized trials in primary care: a practical approach. Fam Pract 2000;17:192-6.
Article PubMed
48. Wang C, Mamza J, Idris I. Biphasic vs basal bolus insulin regimen in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabet Med 2015;32:585-94.
PubMed
49. Perez A, Reales P, Barahona MJ, Romero MG, Minambres I; HOSMIDIA Study Group. Efficacy and feasibility of basal-bolus insulin regimens and a discharge-strategy in hospitalised patients with type 2 diabetes: the HOSMIDIA study. Int J Clin Pract 2014;68:1264-71.
PubMed
50. Akhtar ST, Mahmood K, Naqvi IH, Vaswani AS. Inpatient management of type 2 diabetes mellitus: does choice of insulin regimen really matter? Pak J Med Sci 2014;30:895-8.
PubMed PMC